Turnstone Biologics

A series of dice with a bag on them illustrating cost cuts

Turnstone lays off 60%, shakes up C-suite to stretch out cash

Turnstone Biologics is reducing its head count by 60% and shaking up its C-suite in order to keep the cash flowing to its sole clinical-stage candidate.

James Waldron Oct 11, 2024 8:05am

target reach ladder climb meet win beat competition

Turnstone narrows cell therapy focus to 'high unmet need' tumors

Aug 15, 2024 7:46am

Wall Street stock exchange finance shares share price Nasdaq

Turnstone turns fortunes around with $80M IPO haul

Jul 21, 2023 9:25am

Booted by Big Pharma, Turnstone files IPO to fund cell therapies

Jun 13, 2023 9:40am

Takeda cuts ties to cancer drug landed in $120M Turnstone deal

Jul 28, 2022 7:00am

ASCO: Takeda Oncology ready to stoke partnerships

Jun 9, 2022 7:30am